COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cubicin(R) for Complicated Post-surgical Wound Infections (PSW)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00651131
Recruitment Status : Terminated (terminated due to slow enrollment)
First Posted : April 2, 2008
Last Update Posted : August 30, 2017
Information provided by (Responsible Party):
Cubist Pharmaceuticals LLC

Brief Summary:
The purpose of the study is to describe the clinical efficacy of CUBICIN therapy in patients with superficial and deep post-surgical Gram-positive wound infections

Condition or disease Intervention/treatment Phase
Wound Infections Drug: daptomycin Phase 4

Detailed Description:
A multi-center, single-arm, open-label, non-comparative study to describe the clinical efficacy of CUBICIN therapy in patients with superficial and deep post-surgical Gram-positive wound infections. Adjunctive treatment with aztreonam and/or metronidazole could be given for Gram-negative and/or anaerobic organisms. Patients are to be treated for a period of 7-14 days as specified in the package insert. An evaluation is to be performed on the day CUBICIN treatment is completed (assessment for outcome of cure, improved, failure or unable to evaluate). A follow-up is required for patients with an Investigator response of 'Improved' at the end of treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cubicin(R) for Complicated Post-surgical Wound Infections
Actual Study Start Date : June 1, 2004
Actual Primary Completion Date : March 1, 2005
Actual Study Completion Date : March 1, 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Daptomycin

Intervention Details:
  • Drug: daptomycin
    daptomycin i.v. 4 mg/kg q24h for 7-14 days
    Other Names:
    • Cubicin
    • daptomycin for injection
    • Cubicin (daptomycin for injection)

Primary Outcome Measures :
  1. Investigator's assessment of clinical response based on improvement of signs and symptoms [ Time Frame: End of Therapy ]

Secondary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: first dose to end of therapy ]
  2. eradication of pathogens isolated at admission [ Time Frame: End of Therapy ]
  3. overall therapeutic outcome based on agreement between clinical efficacy and microbiological response [ Time Frame: End of Therapy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Read and signed informed consent form
  • female of childbearing potential, negative pregnancy test result
  • Confirmed diagnosis of post-surgical wound infections known or suspected (based on Gram stain) to be due to Gram-positive organisms obtained within 3 calendar days prior to first dose of study medication
  • Onset of surgical wound infection within 30 days after surgery
  • At least three clinical signs and symptoms of skin infection

Exclusion Criteria:

  • previous systemic antimicrobial therapy exceeding 24 hours duration administered anytime during 72 hours prior to the first dose of study drug
  • Uncomplicated surgical infections (eg, stitch abscesses)
  • osteomyelitis, pneumonia, bacteremia, endocarditis, or urinary tract infection
  • Any type of space infection
  • Conditions requiring surgical removal of wound infection
  • necrotizing fasciitis, synergistic gangrene, Clostridial myonecrosis (gas gangrene), or Fournier's gangrene;
  • Foreign material involved in the post-surgical wound infection
  • Known to be allergic or intolerant to study medication
  • Creatinine Clearance (CLCR) <30 mL/min
  • history of neurological disease (eg, Guillain-Barré, multiple sclerosis)

Layout table for additonal information
Responsible Party: Cubist Pharmaceuticals LLC Identifier: NCT00651131    
Other Study ID Numbers: 3009-011
DAP-4PSW-03-03 ( Other Identifier: Cubist Study Number )
First Posted: April 2, 2008    Key Record Dates
Last Update Posted: August 30, 2017
Last Verified: August 2017
Keywords provided by Cubist Pharmaceuticals LLC:
wound infection
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Wound Infection
Surgical Wound Infection
Surgical Wound
Wounds and Injuries
Postoperative Complications
Pathologic Processes
Anti-Bacterial Agents
Anti-Infective Agents